loader

News by Tag

TORONTO and CAMBRIDGE, MA

Published: Nov 14, 2019

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF…

Published: Nov 14, 2019

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF…

Published: Nov 07, 2019

Dr. Johanne Kaplan highlights need for precision selectivity for the toxic form of amyloid beta in narrated overview ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology com…

Published: Oct 24, 2019

New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology…

Published: Oct 23, 2019

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biot…

Published: Oct 23, 2019

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biot…

Published: Oct 23, 2019

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biot…

Published: Oct 17, 2019

Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on…

Published: Oct 08, 2019

Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology co…